Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Brief description of study

The purpose of this study is to determine if individuals diagnosed with palmoplantar pustulosis (PPP) would benefit from treatment with Deucravacitinib.

Detailed description of study

This is an open label study, and all participants will receive Deucravacitnib (SOTYKTU) for up to 24 weeks. Study visits will occur at the Perelman Center for Advanced Medicine. Participants will be compensated up to $720 for their time, depending on the number of visits completed.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
dermatology,palmoplantar pustulosis,PPP
Age: Between 18 Years - 100 Years
Gender: All

The following is required to be included in this study:

Dermatologist-confirmed diagnosis of PPP for at least 6 months
Moderate-severe PPP
Inadequate response to topical therapy and a candidate for systemic or phototherapy
Willing to discontinue current topical and/or systemic PPP treatments, except for OTC emollients

Updated on 22 Apr 2024. Study ID: 854018

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).